Nasdaq

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

QuidelOrtho Corporation QDEL recently announced that it has been granted a CLIA Waiver by the FDA, which applies to its new Sofia 2 SARS Antigen+ FIA (fluorescent immunoassay). The Sofia 2 SARS ...
FierceBiotech

QuidelOrtho's rapid antigen COVID test is first to receive regular clearance from the FDA

QuidelOrtho's Sofia 2 SARS Antigen+ FIA test returns results within 10 minutes. Once each test is complete, the Sofia 2 system automatically adds the de-identified results to the company's Virena data ...
Nasdaq

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device

Quidel plans initial release to professional and point-of-care segments with a goal of expansion to serve telemedicine and home markets Sofia Q is the latest product in Quidel’s best-selling Sofia ...
Business Wire

Quidel Receives FDA Clearance and CLIA Waiver for Its Point-of-Care Sofia® 2 Immunoassay Analyzer for Use with Sofia Influenza A+B Assay

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has ...